| Title |
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
|
|---|---|
| Published in |
BMC Cancer, October 2015
|
| DOI | 10.1186/s12885-015-1663-5 |
| Pubmed ID | |
| Authors |
Stefanie de Groot, Maaike PG Vreeswijk, Marij JP Welters, Gido Gravesteijn, Jan JWA Boei, Anouk Jochems, Daniel Houtsma, Hein Putter, Jacobus JM van der Hoeven, Johan WR Nortier, Hanno Pijl, Judith R Kroep |
| Abstract |
Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. ClinicalTrials.gov: NCT01304251 , March 2011. |
X Demographics
The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 16% |
| Spain | 2 | 8% |
| Canada | 2 | 8% |
| Mexico | 1 | 4% |
| United Kingdom | 1 | 4% |
| India | 1 | 4% |
| Unknown | 14 | 56% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 21 | 84% |
| Practitioners (doctors, other healthcare professionals) | 3 | 12% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 322 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 322 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 62 | 19% |
| Student > Master | 39 | 12% |
| Researcher | 31 | 10% |
| Other | 28 | 9% |
| Student > Ph. D. Student | 22 | 7% |
| Other | 50 | 16% |
| Unknown | 90 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 82 | 25% |
| Nursing and Health Professions | 42 | 13% |
| Biochemistry, Genetics and Molecular Biology | 29 | 9% |
| Agricultural and Biological Sciences | 18 | 6% |
| Immunology and Microbiology | 6 | 2% |
| Other | 43 | 13% |
| Unknown | 102 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 99. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2023.
All research outputs
#431,118
of 25,630,321 outputs
Outputs from BMC Cancer
#41
of 9,026 outputs
Outputs of similar age
#5,973
of 290,208 outputs
Outputs of similar age from BMC Cancer
#3
of 237 outputs
Altmetric has tracked 25,630,321 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,026 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,208 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 237 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.